GSK plc 6-K, filed Oct 13, 2026
GSK plc (GSK)
6-K
2026-10-13
For: 2026-10-13
View Original
Added on
October 13, 2026
About this 6-K
GSK plc filed this 6-K on October 13, 2026.
GSK plc reported PDMR and closely associated person acquisitions through dividend reinvestment and Share Reward Plan awards, plus a notional ADS purchase, on 2026-10-07, 2026-10-08 and 2026-10-09. AI summary
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the ‘Company’)
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Luke Miels
|
|||
|
b)
|
Position/status
|
Chief Executive Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.5852
|
3
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-08
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Lynn Baxter
|
|||
|
b)
|
Position/status
|
President, Europe
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.5852
|
39
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-08
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
James Ford
|
|||
|
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.5852
|
13
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-08
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
David Redfern
|
|||
|
b)
|
Position/status
|
President Corporate Development
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.5852
|
80
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-08
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Regis Simard
|
|||
|
b)
|
Position/status
|
President, Global Supply Chain
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.5852
|
32
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-08
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Philip Thomson
|
|||
|
b)
|
Position/status
|
President, Global Affairs
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.5852
|
52
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2026-10-08
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Deborah Waterhouse
|
|||
|
b)
|
Position/status
|
CEO, ViiV Healthcare and President, Global Health, GSK
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.5852
|
66
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-08
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Victoria Whyte
|
|||
|
b)
|
Position/status
|
SVP & Company Secretary
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.5852
|
62
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-08
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Neil Falkingham
|
|||
|
b)
|
Position/status
|
PCA of Lynn Baxter (President, Europe)
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on shares held
through the Company’s Share Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.5852
|
64
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-08
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Victoria Whyte
|
|||
|
b)
|
Position/status
|
SVP & Company Secretary
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.5904
|
243
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-08
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Iain Whyte
|
|||
|
b)
|
Position/status
|
PCA of Victoria Whyte (SVP & Company Secretary)
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.5904
|
1,182
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-08
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Maya Martinez-Davis
|
|||
|
b)
|
Position/status
|
President, US
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares (‘ADS’)
ISIN: US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of notional ADS within Ms Martinez-Davis’s GSK
Executive Supplemental Savings Plan account
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$47.0200
|
10.155
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-07
|
|||
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Lynn Baxter
|
|||
|
b)
|
Position/status
|
President, Europe
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.6539
|
7 (partnership shares)
|
|
||
|
|
£17.6539
|
7 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
14 Ordinary Shares
£17.6539
|
|||
|
e)
|
Date
of the transaction
|
2026-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Julie Brown
|
|||
|
b)
|
Position/status
|
Chief Financial Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.6539
|
7 (partnership shares)
|
|
||
|
|
£17.6539
|
7 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
14 Ordinary Shares
£17.6539
|
|||
|
e)
|
Date
of the transaction
|
2026-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
James Ford
|
|||
|
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.6539
|
7 (partnership shares)
|
|
||
|
|
£17.6539
|
7 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
14 Ordinary Shares
£17.6539
|
|||
|
e)
|
Date
of the transaction
|
2026-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
David Redfern
|
|||
|
b)
|
Position/status
|
President, Corporate Development
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.6539
|
7 (partnership shares)
|
|
||
|
|
£17.6539
|
7 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
14 Ordinary Shares
£17.6539
|
|||
|
e)
|
Date
of the transaction
|
2026-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Regis Simard
|
|||
|
b)
|
Position/status
|
President, Global Supply Chain
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.6539
|
7 (partnership shares)
|
|
||
|
|
£17.6539
|
7 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
14
Ordinary Shares
£17.6539
|
|||
|
e)
|
Date
of the transaction
|
2026-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Philip Thomson
|
|||
|
b)
|
Position/status
|
President, Global Affairs
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.6539
|
7 (partnership shares)
|
|
||
|
|
£17.6539
|
7 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
14 Ordinary Shares
£17.6539
|
|||
|
e)
|
Date
of the transaction
|
2026-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Deborah Waterhouse
|
|||
|
b)
|
Position/status
|
CEO, ViiV Healthcare and President, Global Health, GSK
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.6539
|
7 (partnership shares)
|
|
||
|
|
£17.6539
|
7 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
14 Ordinary Shares
£17.6539
|
|||
|
e)
|
Date
of the transaction
|
2026-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Victoria Whyte
|
|||
|
b)
|
Position/status
|
SVP & Company Secretary
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.6539
|
7 (partnership shares)
|
|
||
|
|
£17.6539
|
7 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
14 Ordinary Shares
£17.6539
|
|||
|
e)
|
Date
of the transaction
|
2026-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Neil Falkingham
|
|||
|
b)
|
Position/status
|
PCA of Lynn Baxter (President, Europe)
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.6539
|
7 (partnership shares)
|
|
||
|
|
£17.6539
|
7 (matching shares)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
14 Ordinary Shares
£17.6539
|
||||
|
e)
|
Date
of the transaction
|
2026-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
David Redfern
|
|||
|
b)
|
Position/status
|
President Corporate Development
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.6650
|
7
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Neil Falkingham
|
|||
|
b)
|
Position/status
|
PCA of Lynn Baxter (President, Europe)
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.6650
|
7
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
David Redfern
|
|||
|
b)
|
Position/status
|
President Corporate Development
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on Ordinary Shares
held within an ISA
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.6650
|
20
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Victoria Whyte
|
|||
|
b)
|
Position/status
|
SVP & Company Secretary
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2026 on Ordinary Shares
held within an ISA
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£17.6650
|
17
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|||
|
e)
|
Date
of the transaction
|
2026-10-09
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
Registered in England & Wales:
No.
3888792
Registered Office:
79 New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: October
12, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|